

# Product Portfolio



# 34 years of history


**Pharmazac** is a Greek Privately-owned company, established in 1986, initially focusing in the Distribution of Pharmaceutical products in the areas of CVS, CNS, Urology, Oncology, Musculoskeletal and Food Supplements. Having established itself as a reliable local distributor, Pharmazac has signed strategic partnerships as exclusive Partner of multinational companies like Takeda and GE Healthcare.

2016 was a year of reformulation and the focus shifted in developing, manufacturing, marketing and Licensing Out Pharmazac's own generic products.

Subsequently **Pharmazac** invested heavily in both, state of the art R&D facilities and, attracting industry experts to help in this new strategic repositioning.

In parallel, **Pharmazac** invested in upgrading all necessary infrastructure needed to support the R&D project. Significant investment and resources were allocated to upgrade the RA, Supply/Chain and Business Development & Licensing departments as well.

By the end of 2021, **Pharmazac** aims at having finalized 11 new product developments fully developed in its own R&D facilities.



# R&D

**Pharmazac** has been continuously investing in its in-house development capabilities. In 2016 an **EU-GMP certified R&D facility** was constructed. It is a 700 sq.m. state of the art Pilot Batches Manufacturing facility (Class D Laboratory) that covers a wide spectrum of pharmaceutical forms and ensures the quality and reliability of our projects in full compliance with cGMP and high industry standards.

In parallel, a dedicated analytical team operates the QC laboratory which supports the in-house development projects and undertakes the testing & release of Clinical batches.

**Pharmazac's** Development operations are supported by a strong team of portfolio and patent scientists, formulation and manufacturing experts, high qualified QC analysts and clinical experts.

**Pharmazac's** Development projects include several patent expiring generics as well as niche and value added products.



# Partnering

**Pharmazac** has a long history of building successful relations with its Partners in terms of Distribution, Co-Promotion and Contract Manufacturing.

In view of the strategic repositioning (investing in R&D formulations), the focus and resources are now being utilized towards establishing successful Co – Development and Licensing models of cooperation.



# Product List 2020

Product	Pharmaceutical Form	Strengths	Therapeutic Category	Dossier Status
<b>Rosuvastatin + Ezetimibe</b>	Tablets	5mg+10mg 10mg+10mg 20mg+10mg 40mg+10mg	Cholesterol & Triglyceride regulator	Ready
<b>*Prednisolone</b>	Oral solution	1mg/ml 10mg/ml	Corticosteroids for systemic use	Ready
<b>*Cholecalciferol (Vitamin D3)</b>	Hard gel capsules	10.000 IU 25.000 IU	Treatment or prevention of vitamin D3 deficiency	Ready
<b>Sitagliptin Hydrochloride + Metformin</b>	F.C. Tablets	50mg+850mg 50mg+1000mg	Oral antidiabetic	Ready
<b>Sitagliptin Hydrochloride</b>	F.C. Tablets	25mg 50mg 100mg	Oral antidiabetic	Q4 2020
<b>Micafungin</b>	Powder for solution for infusion	100mg/10ml 50mg/10ml	Antifungal	Q1 2021
<b>Rivaroxaban</b>	F. C. Tablets	2,5mg 10mg 15mg 20mg	Oral anticoagulant	Q2 2021



Product	Pharmaceutical Form	Strengths	Therapeutic Category	Dossier Status
<b>Ticagrelor</b>	F.C. Tablets	60mg 90mg	Platelet aggregation inhibitor	Q2 2021
<b>Linagliptin</b>	F.C. Tablets	5mg	Oral antidiabetic	Q4 2021
<b>Apixaban</b>	F.C. Tablets	2.5mg 5mg	Oral anticoagulant	Q1 2022
<b>Linagliptin + Metformin</b>	F.c. tablets	2.5mg+850mg 2.5mg+1000mg	Oral antidiabetic	Q2 2022
<b>Vortioxetine</b>	F.C. Tablets	5mg 10mg 20mg	Antidepressant	Expected within 2023
<b>Dapagliflozin</b>	F.C. Tablets	5mg 10mg	Oral antidiabetic	Expected within 2023
<b>Dapagliflozin + Metformin</b>	F.C. Tablets	5mg+850mg 5mg+1000mg 10mg+850mg 10mg+1000mg	Oral antidiabetic	Expected within 2023

\* Niche Product

Products which are subject to patent are currently not offered or made available in countries where patents are in force. No orders or deliveries, prior to patent expiry are possible.

# Contact Pharmazac

## Athens

### Business Development & Licensing

Naousis 31

Athens, 10447

Greece

Tel.: +30 210 341 8889

Fax.: + 30 210 866 1262

E-mail.: [bd@pharmazac.com](mailto:bd@pharmazac.com)

### Exports

Naousis 31

Athens, 10447

Greece

Tel.: +30 210 341 8889

Fax.: + 30 210 866 1262

E-mail.: [exports@pharmazac.com](mailto:exports@pharmazac.com)

# London

---

Corporate Development  
152-160 City Street  
London EC1V 2NX  
United Kingdom  
Tel.: + 44 7583444774  
E-mail.: [cd@pharmazac.com](mailto:cd@pharmazac.com)



[www.pharmazac.com](http://www.pharmazac.com)